A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Harb, WA
  • Sessa, C
  • Hirte, Holger
  • Kaye, SB
  • Simantov, R
  • Banerjee, SN
  • Christinat, A
  • Sternberg, DW
  • Singh, M
  • Light, R
  • Poondru, S

publication date

  • May 20, 2011